A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone and placebo with docetaxel, prednisone and bevacizumab in men with metastatic castration-resistant prostate cancer(mCRPC): Survival results of CALGB 90401 - Kelly, WK (J Clin Oncol, 2010)
Abstract LBA4511.